Meeting
2013 ASCO Annual Meeting
Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial.
Authors
Chris Parker
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Chris Parker , Jose E. Garcia-Vargas , C. Gillies O'Bryan-Tear , Fang Fang , Nicholas J. Vogelzang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00699751
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5060)
DOI
10.1200/jco.2013.31.15_suppl.5060
Abstract #
5060
Poster Bd #
38C
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).
First Author: Bertrand F. Tombal
Poster
2015 Genitourinary Cancers Symposium
External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
First Author: Steven E. Finkelstein
Poster
2013 ASCO Annual Meeting
Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.
First Author: Nicholas J. Vogelzang
Poster
2016 ASCO Annual Meeting
Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.
First Author: Michael J. Morris